Why Investors Shouldn’t Overlook the Booming Medical Marijuana Sector
Medical Marijuana Continues to Grow
No, it’s not as sexy as the recreational marijuana industry, but medical marijuana is quietly taking over the United States. Whether Republican, Democrat, or anything in between, it doesn’t seem to matter when it comes to medical marijuana, making it one of the few non-partisan things left these days in the country.
A shining example of why investors ought to pay attention to medical marijuana stocks is Oklahoma.
The state has two Republican senators and a Republican governor—hardly a beacon of progressivism. And yet Oklahoma has not only wholeheartedly accepted medical marijuana, but has also become one of the most pot-crazy states in the union.
One year ago, when Oklahoma voters approved a medical marijuana bill, officials thought about 80,000 patients, or about two percent of the state’s population, would register in the first year of a legal medical marijuana program. (Source: “One year after SQ 788 vote, Oklahoma near No. 1 for patients among medical marijuana states,” Tulsa World, June 26, 2019.)
As of last week, the Oklahoma Medical Marijuana Authority (OMMA) puts the number of registered patients at about 3.5% of the state’s population, with little sign of applications slowing. As of May, that participation rate puts Oklahoma near No. 1 among the 33 states that have some form of medical cannabis legislation in place.
Those numbers actually put it ahead of California when it comes to a per capita measurement. Of course, some of that may be due to the fact that California has legalized recreational pot, no doubt siphoning some users away from the medical pot sector. But still, that’s very impressive.
After all, when one thinks of high-flying pot smokers, one would imagine they’d be from some beach town in Cali rather than the plains of Oklahoma. But it appears that either location would suit them just fine.
So what’s the reason for Oklahoma’s success? Something I’ve been prattling on about for ages now: government getting out of the way. Comparatively low financial barriers, combined with a lack of restrictions on qualifying conditions, allowed for a wide cast of people to apply for licenses, according to the OMMA. (Source: Ibid.)
Other states, like Maine, have similarly removed qualifying conditions from their medical marijuana programs, much to the benefit of the industry. Moves like this have helped increase access to marijuana and therefore have benefited pot businesses greatly.
The OMMA has approved 3,211 grower licenses, 1,548 dispensary licenses, and 859 processor licenses. That’s a far cry from other states, which have only begun to open up a handful of licensed dispensaries for medical marijuana, despite having legalized its use several years ago.
So the numbers are there when we consider the future of the medical marijuana industry. Let’s take a step back and now look at the big picture.
Medical Marijuana Stocks’ Future
While much of the focus has been on recreational marijuana stocks as Canada became the first modern economy to legalize its use, there’s one thing that people seem to have forgotten in the rush of excitement: recreational marijuana may be many years away as a global legal trade.
While I have no doubt that it will soon come to be a multi-billion-dollar, worldwide industry, with many investors today seeing major benefits from getting in early, I also know that it will be a long and arduous process to see the product legalized around the globe.
Hell, look at the U.S. and its difficulties with legalization. Do you think other countries with less liberal values are going to have an easier time?
Which is all just a long way of saying you have to learn how to walk before you can run. Walking, in this case, may be the easier sell of legalizing medical marijuana.
There is still a lot of stigma surrounding marijuana. Many people have lived their entire lives with the drug being considered contraband and illicit by governments the world over.
It’s only a recent development that people have begun to consider the prospect that marijuana may, in fact, be an acceptable vice not all that different from alcohol.
One way to sell marijuana to these folks is to package it as a medicine that can potentially have a number of positive effects. Whether it be used to treat certain aspects of cancer, epilepsy, or pain, marijuana has a number of applications in the medical field that could benefit millions of people.
Furthermore, marijuana could help alleviate much of the opioid epidemic if it is found to be a suitable alternative pain medication.
While this is all theoretical at the moment, legalization of medical marijuana would allow companies to engage in full-throttle pursuits of pot as a medicine.
So there’s certainly potential locked away within medical marijuana that is currently not being explored due to U.S. restrictions.
While other countries have legalized medical marijuana, much of the research power of “Big Pharma” lays within American borders and therefore is being stifled by the lack of pot law reform. Not to mention that Big Pharma is far less likely to pursue an area of research if huge swaths of its potential market (much of the U.S.) is closed off to it.
Medical marijuana stocks could be one of the best ways to make money in the near future if the U.S. decides to take a piecemeal approach to marijuana and it legalizes medical pot before going full bore on recreational products.
I could very easily see medical marijuana reform being passed within the next year, since it’s an issue that has appeal across the political spectrum—as demonstrated by Oklahoma. Recreational pot, meanwhile, remains rather divisive.
Consider medical marijuana to be the gateway drug to the “harder stuff,” in this case, recreational pot.
Medicinal weed is easier to sell to naysayers and has the capacity to bring relief to millions of people, not to mention that medical marijuana stocks would likely yield big returns for investors.